Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Boehringer Ingelheim
Healthtrust
Chubb
Fish and Richardson
Accenture
Merck
Covington
Cipla

Generated: May 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,459,561

« Back to Dashboard

Which drugs does patent 7,459,561 protect, and when does it expire?

Patent 7,459,561 protects CRESEMBA and is included in two NDAs.

This patent has twenty-two patent family members in nineteen countries.
Summary for Patent: 7,459,561
Title:N-substituted carbamoyloxyalkyl-azolium derivatives
Abstract: N-substituted carbamoyloxyalkyl-azolium derivatives which have antifungal activity and are useful for the treatment of fungal diseases.
Inventor(s): Fukuda; Hiroshi (Tokyo, JP), Hayase; Tadakatsu (Chigasaki, JP), Mizuguchi; Eisaku (Kamakura, JP), Shimma; Nobuo (Chigasaki, JP), Ohwada; Jun (Kamakura, JP), Oikawa; Nobuhiro (Kawasaki, JP), Sakaitani; Masahiro (Chigasaki, JP), Tsukazaki; Masao (Fujisawa, JP), Umeda; Isao (Yokohama, JP)
Assignee: Basilea Pharmaceutica AG (Basel, CH)
Application Number:11/504,299
Patent Claim Types:
see list of patent claims
Compound;

Drugs Protected by US Patent 7,459,561

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Astellas CRESEMBA isavuconazonium sulfate CAPSULE;ORAL 207500-001 Mar 6, 2015 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Astellas CRESEMBA isavuconazonium sulfate POWDER;IV (INFUSION) 207501-001 Mar 6, 2015 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,459,561

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
99121694Nov 2, 1999

Non-Orange Book US Patents Family Members for Patent 7,459,561

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,189,858 N-phenyl substituted carbamoyloxyalkyl-azolium derivatives ➤ Try a Free Trial
6,812,238 N-substituted carbamoyloxyalkyl-azolium derivatives ➤ Try a Free Trial
7,151,182 Intermediates for N-substituted carbamoyloxyalkyl-azolium derivatives ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 7,459,561

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 029403 ➤ Try a Free Trial
Austria 291575 ➤ Try a Free Trial
Australia 2835201 ➤ Try a Free Trial
Australia 777859 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Argus Health
McKinsey
Deloitte
Merck
Cantor Fitzgerald
Cipla
US Department of Justice
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.